Ciprofloxacin intratympanic - Otonomy

Drug Profile

Ciprofloxacin intratympanic - Otonomy

Alternative Names: AuriPro™; Ciprofloxacin otic suspension - Otonomy; OTIPRIO; OTO-201

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Otonomy
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Phase III Otitis externa

Most Recent Events

  • 02 Mar 2017 Otonomy has patent protection for ciprofloxacin in USA (Otonomy Form 10-K, March 2017).
  • 05 Jan 2017 Positive topline efficacy data from a phase III trial in Otitis externa (In adolescents, In children, In the elderly, In infants, In adults)released by Otonomy
  • 01 Dec 2016 Otonomy completes a phase-III trial in Otitis externa (In adolescents, In children, In the elderly, In infants, In adults) in USA and Canada (Intratympanic) (NCT02801370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top